Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy

NMR in Biomedicine

Volumn 21, Issue 10, 2008, Pages 1066-1075

  Silveri, M M ^a,b   Dikan, J ^a   Ross, A J ^a,b   Jensen, J E ^a,b   Kamiya, T ^c   Kawada, Y ^c   Renshaw, P F ^a,b   Yurgelun Todd, D A ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

NTP; 31P MRS; Anterior cingulate; Citicoline; Phosphocreatine; Phospholipids

Indexed keywords

31P MRS; ANTERIOR CINGULATE; ANTERIOR CINGULATE CORTICES; CITICOLINE; HIGH-ENERGY PHOSPHATE; MEMBRANE PHOSPHOLIPIDS; PHOSPHOCREATINE; PHOSPHOLIPID MEMBRANE;

BIOCHEMISTRY; BIOMOLECULES; CELL MEMBRANES; CYTOLOGY; MAGNETIC RESONANCE SPECTROSCOPY; METABOLITES; PHOSPHATES; PHOSPHOLIPIDS; PHOSPHORUS;

BRAIN;

CITICOLINE; NOOTROPIC AGENT; PHOSPHORUS;

ARTICLE; DRUG EFFECT; FEMALE; FRONTAL LOBE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

CYTIDINE DIPHOSPHATE CHOLINE; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PHOSPHORUS;

EID: 59849104558     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1281     Document Type: Article

References (67)

1. Agut J, Ortiz JA, Wurtman RJ. Cytidine (5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis. Ann N Y Acad Sci. 2000; 920: 332-335.
2. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5' dipho-sphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther. 1979; 239: 52-61.
3. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995; 17 (Suppl B): 1-54.
4. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res. 1995; 17: 281-284.
5. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006; 231: 490-504.
6. Blusztajn JK, Liscovitch M, Richardson UI. Synthesis of acetyl-choline from choline derived from phosphatidylcholine in a human neuronal cell line. Proc Natl Acad Sci USA. 1987; 84: 5474-5477.
7. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995; 56: 637-660.
8. Alvarez XA, Laredo M, Corzo D, Fernandez-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol. 1997; 19: 201-210.
9. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ. Citicoline improves verbal memory in aging. Arch Neurol. 1996; 53: 441-448.
10. Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, executive function, and fractional anisotropy: a diffusion tensor MR imaging study. AJNR Am JNeuroradiol. 2007; 28: 226-235.
11. Hazlett EA, Buchsbaum MS, Mohs RC, Spiegel-Cohen J, Wei TC, Azueta R, Haznedar MM, Singer MB, Shihabuddin L, Luu-Hsia C, Harvey PD. Age-related shift in brain region activity during successful memory performance. Neurobiol Aging. 1998; 19: 437-445.
12. Garraux G, Salmon E, Degueldre C, Lemaire C, Laureys S, Franck G. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage. 1999; 10: 149-162.
13. Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J. Cereb Blood Flow Metab. 1982; 2: 163-171.
14. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J. Nucl Med. 1995; 36: 1141-1149.
15. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, Grady C, Pietrini P, Eidelberg D. The metabolic topography of normal aging. J. Cereb Blood Flow Metab. 1996; 16: 385-398.
16. Murphy DG, DeCarli C, McIntosh AR, Daly E, Mentis MJ, Pietrini P, Szczepanik J, Schapiro MB, Grady CL, Horwitz B, RapoportSI. Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch Gen Psychiatry. 1996; 53: 585-594.
17. Yoshii F, Barker WW, Chang JY, Loewenstein D, Apicella A, Smith D, Boothe T, Ginsberg MD, Pascal S, Duara R. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J. Cereb Blood Flow Metab. 1988; 8: 654-661.
18. Beckman KB, Ames BN. Mitochondrial aging: open questions. Ann N Y Acad Sci. 1998; 854: 118-127.
19. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000; 29: 222-230.
20. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972; 20: 145-147.
21. Lenaz G, Bovina C, D'Aurelio M, Fato R, Formiggini G, Genova ML, Giuliano G, Merlo Pich M, Paolucci U, Parenti Castelli G, Ventura B. Role of mitochondria in oxidative stress and aging. Ann N Y Acad Sci. 2002; 959: 199-213.
22. Melov S. Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging. Ann N Y Acad Sci. 2000; 908: 219-225.
23. Miquel J. An update on the oxygen stress-mitochondrial mutation theory of aging: genetic and evolutionary implications. Exp Gerontol. 1998; 33: 113-126.
24. Villa RF, Marzatico F, Benzi G. Changes induced by ischemia on some cerebral enzymatic activities related to energy transduction and amino acid metabolism. Neurochem Res. 1983; 8: 269-290.
25. Villa RF, Turpeenoja L, Magri G, Gorini A, Ragusa N, Giuffrida-Stella AM. Effect of hypoxia on mitochondrial protein compo-sition of cerebral cortex during aging. Neurochem Res. 1991; 16: 821-826.
26. Wallace DC, Brown MD, Melov S, Graham B, Lott M. Mitochon-drial biology, degenerative diseases and aging. Biofactors. 1998; 7: 187-190.
27. Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev. 2006; 52: 389-397.
28. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000; 60: 989-992.
29. Kennedy EP, Weiss SB. The function ofcytidine coenzymes in the biosynthesis of phospholipides. J. Biol Chem. 1956; 222: 193-214.
30. Voelker DR. Phosphatidylserine functions as the major precursor of phosphatidylethanolamine in cultured BHK-21 cells. Proc Natl Acad Sci USA. 1984; 81: 2669-2673.
31. Voelker DR, Kennedy EP. Cellular and enzymic synthesis of sphingomyelin. Biochemistry. 1982; 21: 2753-2759.
32. Babb SM, Appelmans KE, Renshaw PF, Wurtman RJ, Cohen BM. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl). 1996; 127: 88-94.
33. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA. 1995; 274: 902-907.
34. Cohen J, Forman S, Braver T, Casey B, Servan-Schreiber D, Noll D. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapp. 1994; 1: 293-304.
35. Eyster KM. The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist. Adv Physiol Educ. 2007; 31: 5-16.
36. Alberghina M, Viola M, Serra I, Mistretta A, Giuffrida AM. Effect of CDP-choline on the biosynthesis of phospholipids in brain regions during hypoxic treatment. J. Neurosci Res. 1981; 6: 421-433.
37. Benzi G, Arrigoni E, Pastoris O, Villa RF, Dossena M, Agnoli A, Giuffrida AM. Drug action on the metabolic changes induced by acute hypoxia on synaptosomes from the cerebral cortex. J. Cereb Blood Flow Metab. 1982; 2: 229-239.
38. Serra I, Alberghina M, Viola M, Mistretta A, Giuffrida AM. Effect of CDP-choline on the biosynthesis of nucleic acids and proteins in brain regions during hypoxia. Neurochem Res. 1981; 6: 607-618.
39. Villa RF, Ingrao F, Magri G, Gorini A, Reale S, Costa A, Ragusa N, Avola R, Giuffrida-Stella AM. Effect of CDP-choline treatment on mitochondrial and synaptosomal protein composition in different brain regions during aging. Int J Dev Neurosci. 1993; 11: 83-93.
40. Benzi G, Pastoris O, Dossena M, Marzatico F, Villa RF, Dagani F. Factors involved in the age-related alteration in the efficiency of the brain bioenergetics. Mech Ageing Dev. 1990; 56: 155-168.
41. Mandel P, Edel-Harth S. Free nucleotides in the rat brain during post-natal development. J. Neurochem. 1966; 13: 591-595.
42. Farber SA, Slack BE, Blusztajn JK. Acceleration of phosphatidyl-choline synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. FASEB J. 2000; 14: 2198-2206.
43. Farooqui AA, Ong WY, Horrocks LA. Biochemical aspects of neurodegeneration in human brain: involvement of neural mem-brane phospholipids and phospholipases A2. Neurochem Res. 2004; 29: 1961-1977.
44. Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, Renshaw PF. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002; 161: 248-254.
45. Baburina I, Jackowski S. Cellular responses to excess phospholi-pid. J. Biol Chem. 1999; 274: 9400-9408.
46. First MB (ed.). Structured Clinical Interview for DSM-IV Axis I Disorders (Clinical Version). American Psychiatric Association: Arlington, VA, 1997.
47. Jensen JE, Drost DJ, Menon RS, Williamson PC. In vivo brain (31)P-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed. 2002; 15: 338-347.
48. Hans-Joachim Kretschmann, Weinrich W. Cranial Neuroimaging and Clinical Neuroanatomy. Thieme Publishing Group: New York, 1992.
49. Damasio AR. Time-locked multiregional retroactivation: a systems-level proposal for the neural substrates of recall and recognition. Cognition. 1989; 33: 25-62.
50. Gyulai L, Roth Z, Leigh JS Jr, Chance B. Bioenergetic studies of mitochondrial oxidative phosphorylation using 31phosphorus NMR. J. Biol Chem. 1985; 260: 3947-3954.
51. Nioka S, Smith DS, Chance B, Subramanian HV, Butler S, Katzenberg M. Oxidative phosphorylation system during steady-state hypoxia in the dog brain. J. Appl Physiol. 1990; 68: 2527-2535.
52. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edition). Erlbaum: Hillsdale, NJ, 1988.
53. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem. 1985; 54: 831-862.
54. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science. 1981; 211: 448-452.
55. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J. 1992; 281(Pt 1): 21-40.
56. Chance B, Eleff S, Leigh JS Jr. Noninvasive, nondestructive approaches to cell bioenergetics. Proc Natl Acad Sci USA. 1980; 77: 7430-7434.
57. Chance B, Leigh JS, Smith DS, Nioka S, Clark BJ. Phosphorus magnetic resonance spectroscopy studies of the role of mitochondria in the disease process. Ann N Y Acad Sci. 1986; 488: 140-153.
58. 31P-MRS in the human brain with mental fatigue. Neuropsychobiology. 1999; 39: 214-218.
59. Agut J, Lopez GCI, Ortiz JA, Wurtman RJ. Oral cytidine 5'-diphosphate choline administration to rats increases brain phospholipid levels. Ann N Y Acad Sci. 1993; 695: 318-320.
60. '-cytidinediphosphocholine can affect brain phospho-lipid composition by increasing choline and cytidine plasmalevels. J. Neurochem. 1995; 65: 889-894.
61. Gimenez R, Soler S, Aguilar J. Cytidine diphosphate choline administration activates brain cytidine triphosphate:phosphocho-line cytidylytransferase in aged rats. Neurosci Lett. 1999; 273: 163-166.
62. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J. Pharmacokinet Pharmacodyn. 2006; 33: 227-279.
63. Sauro HM. Simulation of biochemical networks: cellular networks as dynamic control systems. ConfProc IEEE Eng Med Biol Soc. 2006; 1: 44-50.
64. Hetherington HP, Spencer DD, Vaughan JT, Pan JW. Quantitative (31)P spectroscopic imaging of human brain at 4 Tesla: assessment of gray and white matter differences of phosphocreatine and ATP. Magn Reson Med. 2001; 45: 46-52.
65. Mason GF, Chu WJ, Vaughan JT, Ponder SL, Twieg DB, Adams D, Hetherington HP. Evaluation of 31P metabolite differences in human cerebral gray and white matter. Magn Reson Med. 1998; 39: 346-353.
66. 31P NMR detection of mobile dog brain phospholipids. Magn Reson Med. 1986; 3: 432-439.
67. 31P NMR spectroscopic study. Magn Reson Med. 1988; 6: 296-299.